EGFR and cancer: Trastuzumab (Herceptin), Cetuximab (Erbitux), Panitumumab (Vectibix), and Nimotuzumab (BioMAb) have been approved, recently, for the treatment of EGFR positive cancers by targeting the extracellular domain of EGFR.